Seiichi Hayato

1.1k total citations
26 papers, 855 citations indexed

About

Seiichi Hayato is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Seiichi Hayato has authored 26 papers receiving a total of 855 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Seiichi Hayato's work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Thyroid Cancer Diagnosis and Treatment (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Seiichi Hayato is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Thyroid Cancer Diagnosis and Treatment (5 papers) and Lung Cancer Treatments and Mutations (5 papers). Seiichi Hayato collaborates with scholars based in Japan, United States and United Kingdom. Seiichi Hayato's co-authors include Takuya Suzuki, Toshiyuki Tamai, Takuji Okusaka, Hiromitsu Kumada, Masafumi Ikeda, Kiwamu Okita, Kenji Ikeda, Masatoshi Kudo, Seiji Kawazoe and Ziad Hussein and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Cancer Science.

In The Last Decade

Seiichi Hayato

26 papers receiving 839 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Seiichi Hayato Japan 13 376 259 212 184 159 26 855
Dawn M. Carlson United States 15 572 1.5× 221 0.9× 194 0.9× 360 2.0× 187 1.2× 44 1.1k
Celina Ang United States 16 330 0.9× 338 1.3× 219 1.0× 170 0.9× 127 0.8× 51 956
Rajendra Ramsamooj United States 14 154 0.4× 231 0.9× 152 0.7× 133 0.7× 205 1.3× 32 938
Kiyokazu Hiwatashi Japan 17 333 0.9× 317 1.2× 134 0.6× 67 0.4× 187 1.2× 34 913
Kazuho Imanaka Japan 14 354 0.9× 171 0.7× 306 1.4× 84 0.5× 344 2.2× 29 901
Ki Mun Kang South Korea 20 288 0.8× 501 1.9× 413 1.9× 273 1.5× 122 0.8× 71 1.4k
Takashi Niizeki Japan 22 747 2.0× 326 1.3× 209 1.0× 228 1.2× 359 2.3× 70 1.2k
Shuichi Aoki Japan 15 107 0.3× 549 2.1× 252 1.2× 79 0.4× 133 0.8× 54 1.1k
John Frye United States 10 148 0.4× 286 1.1× 172 0.8× 101 0.5× 100 0.6× 24 754
Daichi Takizawa Japan 16 408 1.1× 128 0.5× 159 0.8× 91 0.5× 270 1.7× 57 821

Countries citing papers authored by Seiichi Hayato

Since Specialization
Citations

This map shows the geographic impact of Seiichi Hayato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seiichi Hayato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seiichi Hayato more than expected).

Fields of papers citing papers by Seiichi Hayato

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seiichi Hayato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seiichi Hayato. The network helps show where Seiichi Hayato may publish in the future.

Co-authorship network of co-authors of Seiichi Hayato

This figure shows the co-authorship network connecting the top 25 collaborators of Seiichi Hayato. A scholar is included among the top collaborators of Seiichi Hayato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seiichi Hayato. Seiichi Hayato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hayato, Seiichi, Lora Hamuro, Toshio Shimizu, et al.. (2025). Pharmacokinetic and Exposure–Response Modeling Support Body Surface Area‐Based Dosing of Farletuzumab Ecteribulin in Japanese Patients with Solid Tumors. The Journal of Clinical Pharmacology. 65(6). 751–762. 1 indexed citations
2.
Sasaki, T., Takayuki Katsube, Seiichi Hayato, et al.. (2025). Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan. Journal of Pharmacokinetics and Pharmacodynamics. 52(1). 10–10. 1 indexed citations
3.
Majid, Oneeb, Youfang Cao, Brian A. Willis, et al.. (2024). Population pharmacokinetics and exposure–response analyses of safety (ARIA‐E and isolated ARIA‐H) of lecanemab in subjects with early Alzheimer's disease. CPT Pharmacometrics & Systems Pharmacology. 13(12). 2111–2123. 6 indexed citations
4.
5.
Willis, Brian A., Ziad Hussein, Seiichi Hayato, et al.. (2023). Exposure‐response modeling to describe the change in brain amyloid following lecanemab administration in patients with early Alzheimer’s disease. Alzheimer s & Dementia. 19(S21). 1 indexed citations
6.
7.
Hayato, Seiichi, Osamu Takenaka, Ishani Landry, et al.. (2022). Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease. CPT Pharmacometrics & Systems Pharmacology. 11(12). 1578–1591. 26 indexed citations
8.
Okusaka, Takuji, Kenji Ikeda, Masatoshi Kudo, et al.. (2021). Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. Journal of Gastroenterology. 56(6). 570–580. 10 indexed citations
9.
10.
Hayato, Seiichi, et al.. (2018). Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer. Cancer Chemotherapy and Pharmacology. 82(6). 971–978. 18 indexed citations
11.
Gaspar, Nathalie, Michela Casanova, Francisco Bautista, et al.. (2018). Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS).. Journal of Clinical Oncology. 36(15_suppl). 11527–11527. 25 indexed citations
12.
Hussein, Ziad, Hitoshi Mizuo, Seiichi Hayato, Masayuki Namiki, & Robert Shumaker. (2017). Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor. European Journal of Drug Metabolism and Pharmacokinetics. 42(6). 903–914. 58 indexed citations
13.
Gaspar, Nathalie, Rajkumar Venkatramani, Stefan Bielack, et al.. (2017). Single-agent dose-finding cohort of a phase 1/2 study of lenvatinib (LEN) in children and adolescents with refractory or relapsed solid tumors.. Journal of Clinical Oncology. 35(15_suppl). 10544–10544. 2 indexed citations
14.
Ikeda, Kenji, Masatoshi Kudo, Seiji Kawazoe, et al.. (2016). Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. Journal of Gastroenterology. 52(4). 512–519. 267 indexed citations
15.
Ikeda, Masafumi, Takuji Okusaka, Shuichi Mitsunaga, et al.. (2015). Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 22(6). 1385–1394. 141 indexed citations
16.
Kiyota, Naomi, Martin Schlumberger, Kei Muro, et al.. (2015). Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer. Cancer Science. 106(12). 1714–1721. 97 indexed citations
17.
Hayato, Seiichi, Setsuo Hasegawa, Seiichiro Hojo, et al.. (2011). Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes. European Journal of Clinical Pharmacology. 68(5). 579–588. 12 indexed citations
18.
Ikawa, Kazuro, et al.. (2008). Penetration and Exposure of Cefotiam into the Peritoneal Fluid of Abdominal Surgery Patients after Intravenous Administration. Journal of Chemotherapy. 20(3). 319–323. 4 indexed citations
19.
Ikawa, Kazuro, Norifumi Morikawa, Seiichi Hayato, et al.. (2007). Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients. International Journal of Antimicrobial Agents. 30(3). 270–273. 25 indexed citations
20.
Ikawa, Kazuro, et al.. (2006). Development of Software Support Tool for Planning Administration of Biapenem, a Carbapenem Antibacterial Agent, based on Pharmacokinetic/Pharmacodynamic Approach and Monte Carlo Simulation. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 32(7). 622–628. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dawn M. Carlson Breakdown of academic impact, for papers by Celina Ang Breakdown of academic impact, for papers by Rajendra Ramsamooj Breakdown of academic impact, for papers by Kiyokazu Hiwatashi Breakdown of academic impact, for papers by Kazuho Imanaka Breakdown of academic impact, for papers by Ki Mun Kang Breakdown of academic impact, for papers by Takashi Niizeki Breakdown of academic impact, for papers by Shuichi Aoki Breakdown of academic impact, for papers by John Frye Breakdown of academic impact, for papers by Daichi Takizawa
Rankless by CCL
2026